Summary: In NEO.LIFE, Marianne Apostolides examines current research involving MDMA, psilocybin, and ketamine for the treatment of various eating disorders, interweaving the perspective of experts with insights from personal experience.
“With MDMA, the fears people typically have around connecting with others in a vulnerable way—a more intimate way—are decreased,” explains Adele Lafrance, Ph.D., Co-Clinical Investigator of MAPS’ Phase 2 study of MDMA-assisted therapy for eating disorders. “People start to trust their own internal processes, ranging from bodily sensations—including hunger cues—all the way to the experience of emotion.”